Our analysis presents the findings of a network meta-analysis, attemptingto access the main outcomes among EGFR TKIs in NSCLC, exploiting the data of clinicaltrials with gefitinib, erlotinib and afatinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.